8-K: Plus Therapeutics Secures $17 Million in Funding, Advances CNS Cancer Programs Despite Increased Q1 Losses

Plus Therapeutics reported a significantly improved cash position in the first quarter of 2025, fueled by a $15 million private placement and a $2 million grant advance, as it continues to progress its REYOBIQ clinical trials and prepare for the CNSide platform launch, despite a widened net loss of $17.4 million.

Summary

• Plus Therapeutics reported financial results for the first quarter ended March 31, 2025, and provided updates on recent corporate and clinical milestones.
• The company's cash balance significantly improved to $9.9 million at March 31, 2025, from $0.1 million at December 31, 2024.
• Gross proceeds of $15 million were raised through a private placement financing, alongside a $2.0 million grant award advance from the Cancer Prevention and Research Institute of Texas (CPRIT).
• Grant revenue for Q1 2025 was $1.1 million, a decrease from $1.7 million in Q1 2024.
• Total operating loss for Q1 2025 increased to $3.5 million, compared to $3.3 million in the same period of 2024, primarily due to increased legal fees.
• Net loss for Q1 2025 was $17.4 million, or $(1.19) per share, a substantial increase from a net loss of $3.3 million, or $(0.75) per share, in Q1 2024.
• Updated interim data on REYOBIQ was presented at the Nuclear Medicine and Neuro-oncology conference, highlighting its safety and clinical benefit in patients with leptomeningeal metastases (LM).
• Phase 1 clinical trial results for REYOBIQ in recurrent glioblastoma (GBM) were published in Nature Communications, demonstrating potential efficacy with a median overall survival of 17 months for patients receiving a radiation dose >100 Gy, more than double the standard of care.
• The ReSPECT-LM Phase 1 single dose administration trial was completed, and the maximum tolerated and recommended Phase 2 dose was determined.
• REYOBIQ received U.S. FDA Orphan Drug Designation for the treatment of LM in patients with lung cancer and conditional agreement for its proprietary name, rhenium Re186 obisbemeda.
• The management team was strengthened with the addition of Kyle Guse to the Board of Directors, Dr. Michael Rosol as Chief Development Officer, Russell Bradley as President and General Manager of CNSide Diagnostics, and Dr. Jonathan Stein as Medical Director for CNSide Diagnostics.
• The company continues to prepare for the planned commercial launch of the CNSide cerebral spinal fluid (CSF) assay platform in the U.S. in 2025.

Sentiment

Score: 6

Explanation: While the company reported a significantly increased net loss and operating loss, primarily due to non-cash items and legal/financing fees, the substantial improvement in cash position through a successful private placement and grant funding, coupled with positive clinical trial progress for REYOBIQ and strategic management additions, indicates a positive trajectory for its core business and future development. The financial losses are concerning but are offset by the successful capital raise and clinical milestones.

Positives

• Significantly improved cash position to $9.9 million at March 31, 2025, from $0.1 million at December 31, 2024, providing enhanced liquidity.
• Successfully raised $15 million in gross proceeds from a private placement financing, demonstrating investor confidence.
• Secured a $2.0 million grant award advance from CPRIT, accelerating the leptomeningeal metastases (LM) program.
• Presented positive updated interim data for REYOBIQ in LM patients, highlighting safety and clinical benefit.
• Published Phase 1 clinical trial results for REYOBIQ in recurrent glioblastoma (GBM) in a peer-reviewed journal, showing potential efficacy with a median overall survival of 17 months for patients receiving >100 Gy, which is more than double the standard of care.
• Completed the ReSPECT-LM Phase 1 trial and successfully determined the maximum tolerated and recommended Phase 2 dose.
• Received U.S. FDA Orphan Drug Designation for REYOBIQ for LM in lung cancer patients, which can provide development incentives and market exclusivity.
• Received U.S. FDA conditional agreement for the proprietary name REYOBIQ, a step towards commercialization.
• Strengthened the Board of Directors with the addition of industry veteran Kyle Guse.
• Enhanced the management team with key appointments: Dr. Michael Rosol as Chief Development Officer, Russell Bradley as President and General Manager of CNSide Diagnostics, and Dr. Jonathan Stein as Medical Director for CNSide Diagnostics.
• Continued progress towards the planned commercial launch of the CNSide CSF assay platform in the U.S. in 2025.

Negatives

• Net loss significantly increased to $17.4 million in Q1 2025, compared to $3.3 million in Q1 2024.
• Diluted net loss per share worsened to $(1.19) in Q1 2025 from $(0.75) in Q1 2024.
• Total operating loss increased to $3.5 million in Q1 2025 from $3.3 million in Q1 2024, primarily due to increased legal fees.
• Grant revenue decreased to $1.1 million in Q1 2025 from $1.7 million in Q1 2024.
• Incurred substantial financing expenses of $3.211 million and warrant issuance costs of $964 thousand.
• Experienced a large negative change in fair value of derivative instruments of $9.143 million.
• Total stockholders equity (deficit) worsened to $(23.641) million at March 31, 2025, from $(8.949) million at December 31, 2024.

Risks

• The Company's ability to maintain the listing of its common stock on Nasdaq.
• Risks related to a halt in trading or delisting of the Company's common stock on Nasdaq.
• The early stage of the Company's product candidates and therapies.
• Uncertainties relating to the clinical trials of its product candidates and therapies.
• The Company's liquidity and capital resources and its ability to raise additional cash.
• The outcome of the Company's partnering/licensing efforts.
• Risks associated with laws or regulatory requirements applicable to the company.
• Market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field.
• Ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms.
• Challenges associated with radiotherapeutic manufacturing, production, and distribution capabilities necessary to support the Company's clinical trials and any commercial level product demand.
• Material security breach or cybersecurity attack affecting the Company's operations or property.

Future Outlook

Plus Therapeutics anticipates making solid progress in enrolling patients in its REYOBIQ CNS cancer radiotherapeutic clinical trials and proceeding with the planned commercial launch of the CNSide cerebral spinal fluid (CSF) assay platform in the U.S. in 2025, supported by additional anticipated grant funding in 2025. The company expects to continue evaluating REYOBIQ, including through evaluations in additional patient cohorts.

Management Comments

• "We improved our cash position in the first quarter as a result of both a financing and grant support."
• "With the additional cash and further anticipated grant support in 2025, we are well positioned to make solid progress in our 2 key business goals: enrollment in our REYOBIQ CNS cancer radiotherapeutic clinical trials and the planned launch of the CNSide cerebral spinal fluid (CSF) assay platform."

Industry Context

Plus Therapeutics operates in the highly specialized and challenging field of central nervous system (CNS) cancer therapeutics and diagnostics, an area with significant unmet medical needs. Their focus on targeted radiotherapeutics like REYOBIQ and advanced CSF assay platforms like CNSide positions them at the forefront of developing innovative solutions for difficult-to-treat conditions such as recurrent glioblastoma and leptomeningeal metastases. The company's efforts align with broader industry trends towards precision medicine and targeted therapies in oncology, particularly for cancers with limited treatment options and poor prognoses. The successful capital raise and clinical advancements are critical in this capital-intensive and high-risk industry.

Comparison to Industry Standards

• REYOBIQ's Phase 1 clinical trial results for recurrent glioblastoma showed patients receiving a radiation dose >100 Gy achieved a median overall survival of 17 months, which is stated to be "more than double the standard of care." This suggests a potentially significant improvement over existing treatments for this aggressive cancer, which typically has a very poor prognosis.
• The company's development of a CSF assay platform (CNSide) for identifying tumor cells and circulating tumor DNA in cerebrospinal fluid addresses a critical need for improved diagnostics and management of leptomeningeal metastases, an area where current diagnostic methods can be challenging and often invasive. This platform aims to provide quantitative analysis and molecular characterization, which could set a new standard for monitoring disease progression and treatment response in LM patients.

Management Changes

Stakeholder Impact

• Shareholders: Experienced dilution from the private placement and an increased number of outstanding shares. The net loss per share also increased. However, the significant capital raise provides crucial funding for ongoing clinical development, potentially enhancing long-term value.
• Patients: Continued progress in REYOBIQ clinical trials and the planned launch of CNSide offer potential new and improved treatment and diagnostic options for difficult-to-treat CNS cancers, addressing significant unmet medical needs.
• Employees: The strengthening of the management team and continued advancement of clinical programs suggest stability and potential growth opportunities within the company.
• Creditors: The substantial improvement in the company's cash position reduces immediate liquidity concerns, potentially improving the company's creditworthiness.

Next Steps

• Enrollment in REYOBIQ CNS cancer radiotherapeutic clinical trials.
• Planned commercial launch of the CNSide cerebral spinal fluid (CSF) assay platform in the U.S. in 2025.
• Further anticipated grant support in 2025.
• Continued evaluation of REYOBIQ, including through evaluations in additional patient cohorts.

Key Dates

Recommendation

Keywords

Plus Therapeutics, PSTV, Radiotherapeutics, CNS cancers, Leptomeningeal metastases, Glioblastoma, REYOBIQ, rhenium Re186 obisbemeda, CNSide, CSF assay, Clinical trials, Orphan Drug Designation, Biotechnology, Pharmaceuticals, Oncology, Neuro-oncology, SEC filing, 8-K, Financial results, Q1 2025, Private placement, Grant funding, Corporate governance, Drug development, Medical devices, Diagnostics